Dianthus Therapeutics (NASDAQ:DNTH) Announces Earnings Results

Dianthus Therapeutics (NASDAQ:DNTH) issued its earnings results on Tuesday. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04, Zacks reports. The company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.

Dianthus Therapeutics Stock Down 6.3 %

Shares of DNTH opened at $21.90 on Thursday. Dianthus Therapeutics has a fifty-two week low of $18.13 and a fifty-two week high of $33.77. The firm’s 50 day moving average price is $22.65 and its 200 day moving average price is $24.94. The company has a market cap of $648.17 million, a P/E ratio of -8.76 and a beta of 1.82.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on DNTH. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday. TD Cowen began coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday. Finally, Guggenheim reissued a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $52.14.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.